Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), filed a Form 4 on September 15, 2026, reporting the acquisition of restricted stock units and stock options under the company's 2024 Equity Incentive Plan.

Key Highlights

  • RSU Grant: Fred Aslan acquired 110,000 shares of Common Stock via a restricted stock unit award at a price of $0 on September 15, 2026.
  • Stock Option Grant: Aslan also acquired an Employee Stock Option (Right to Buy) covering 315,000 shares of Common Stock at an exercise price of $8.91, also dated September 15, 2026.
  • Vesting Schedule: Beginning September 8, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four-year period.
  • Option Expiration: The stock option expires on September 14, 2036.
  • Post-Transaction Ownership: Following the reported transactions, Aslan directly holds 1,604,765 shares of Common Stock and 315,000 derivative securities.
  • Plan Source: The RSU award was granted under the issuer's 2024 Equity Incentive Plan, according to the filing.

Artiva Biotherapeutics CEO Fred Aslan Receives RSUs and Options on September 15, 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Fred Aslan, who serves as both Chief Executive Officer and Director of Artiva Biotherapeutics, Inc., received two equity awards on September 15, 2026. The first is a restricted stock unit award covering 110,000 shares of Common Stock, acquired at $0, granted under the issuer's 2024 Equity Incentive Plan. The filing classifies this transaction with code "A" (acquired) and notes direct ownership.

The second award is an Employee Stock Option granting Aslan the right to buy 315,000 shares of Common Stock at an exercise price of $8.91 per share. The filing states that beginning September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period, with the option set to expire on September 14, 2036. The price of the derivative security is listed as $0 in the filing.

Following both reported transactions, Aslan directly holds 1,604,765 shares of Common Stock, according to the filing. His beneficial ownership of derivative securities following the transaction stands at 315,000. The Form 4 was signed by Jennifer Bush as Attorney-in-Fact on September 15, 2026, and filed on that same date.

What Was Disclosed

The filing reports two equity awards to Artiva Biotherapeutics CEO Fred Aslan on September 15, 2026: a 110,000-share RSU grant and a 315,000-share stock option at $8.91, both under the company's 2024 Equity Incentive Plan, with the option vesting monthly over four years.